Cancer Immunotherapy by Dendritic Cells
Cancerous lesions promote tumor growth, motility, invasion, and angiogenesis via oncogene-driven immunosuppressive leukocyte infiltrates, mainly myeloid-derived suppressor cells, tumor-associated macrophages, and immature dendritic cells (DCs). In addition, many tumors express or induce immunosuppre...
Gespeichert in:
| Veröffentlicht in: | Immunity (Cambridge, Mass.) Mass.), 2008-09, Vol.29 (3), p.372-383 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 383 |
|---|---|
| container_issue | 3 |
| container_start_page | 372 |
| container_title | Immunity (Cambridge, Mass.) |
| container_volume | 29 |
| creator | Melief, Cornelis J.M. |
| description | Cancerous lesions promote tumor growth, motility, invasion, and angiogenesis via oncogene-driven immunosuppressive leukocyte infiltrates, mainly myeloid-derived suppressor cells, tumor-associated macrophages, and immature dendritic cells (DCs). In addition, many tumors express or induce immunosuppressive cytokines such as TGF-β and IL-10. As a result, tumor-antigen crosspresentation by DCs induces T cell anergy or deletion and regulatory T cells instead of antitumor immunity. Tumoricidal effector cells can be generated after vigorous DC activation by Toll-like receptor ligands or CD40 agonists. However, no single immunotherapeutic modality is effective in established cancer. Rather, chemotherapies, causing DC activation, enhanced crosspresentation, lymphodepletion, and reduction of immunosuppressive leukocytes, act synergistically with vaccines or adoptive T cell transfer. Here, I discuss the considerations for generating promising therapeutic antitumor vaccines that use DCs. |
| doi_str_mv | 10.1016/j.immuni.2008.08.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69581789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1074761308003750</els_id><sourcerecordid>69581789</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-3fcfd21fa8b6eb2969acce0a92b3a906acb4ae1dd5a17e1a2784471496dc9c623</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMorq7-A5GCoKfWTJumzUWQ-rWw4EXPIU2nmLJt16QV9t-b0gXBg8JAMvDMm8xDyAXQCCjw2yYybTt2JoopzaOpKDsgJ0BFFjLI6eF0z1iYcUgW5NS5hlJgqaDHZAF5JoRvTshNoTqNNlhNWf3wgVZtd0G5Cx6wq6wZjA4K3GzcGTmq1cbh-f5ckvenx7fiJVy_Pq-K-3WoGU-HMKl1XcVQq7zkWMaCC6U1UiXiMlGCcqVLphCqKlWQIag4yxnLgAleaaF5nCzJ9Zy7tf3niG6QrXHa_0B12I9OcpHmkOXiXxAEA8rzxINXv8CmH23nl5CQphTiGIB7is2Utr1zFmu5taZVdieBysm3bOTsW06-5VSU-bHLffhYtlj9DO0Fe-BuBtBL-zJopdMGvfLKWNSDrHrz9wvfZu6Reg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1550122116</pqid></control><display><type>article</type><title>Cancer Immunotherapy by Dendritic Cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Cell Press Free Archives</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Melief, Cornelis J.M.</creator><creatorcontrib>Melief, Cornelis J.M.</creatorcontrib><description>Cancerous lesions promote tumor growth, motility, invasion, and angiogenesis via oncogene-driven immunosuppressive leukocyte infiltrates, mainly myeloid-derived suppressor cells, tumor-associated macrophages, and immature dendritic cells (DCs). In addition, many tumors express or induce immunosuppressive cytokines such as TGF-β and IL-10. As a result, tumor-antigen crosspresentation by DCs induces T cell anergy or deletion and regulatory T cells instead of antitumor immunity. Tumoricidal effector cells can be generated after vigorous DC activation by Toll-like receptor ligands or CD40 agonists. However, no single immunotherapeutic modality is effective in established cancer. Rather, chemotherapies, causing DC activation, enhanced crosspresentation, lymphodepletion, and reduction of immunosuppressive leukocytes, act synergistically with vaccines or adoptive T cell transfer. Here, I discuss the considerations for generating promising therapeutic antitumor vaccines that use DCs.</description><identifier>ISSN: 1074-7613</identifier><identifier>EISSN: 1097-4180</identifier><identifier>DOI: 10.1016/j.immuni.2008.08.004</identifier><identifier>PMID: 18799145</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Angiogenesis ; Animals ; Antigen Presentation ; Antigens ; Antigens, Neoplasm - immunology ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Cancer therapies ; Cancer Vaccines ; CD4-Positive T-Lymphocytes - immunology ; CD4-Positive T-Lymphocytes - metabolism ; CD8-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - metabolism ; Chemokines ; Cross-Priming ; Dendritic Cells - drug effects ; Dendritic Cells - immunology ; Dendritic Cells - metabolism ; Human papillomavirus ; Humans ; Immune system ; Immunosuppression ; Immunotherapy ; Inflammation - immunology ; Inflammation - metabolism ; Ligands ; Lymph Nodes - immunology ; Lymphocyte Activation - drug effects ; Neoplasms - immunology ; Neoplasms - therapy ; Neoplasms - virology ; Proteins ; Tumors ; Vaccines ; Womens health</subject><ispartof>Immunity (Cambridge, Mass.), 2008-09, Vol.29 (3), p.372-383</ispartof><rights>2008 Elsevier Inc.</rights><rights>Copyright Elsevier Limited Sep 19, 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-3fcfd21fa8b6eb2969acce0a92b3a906acb4ae1dd5a17e1a2784471496dc9c623</citedby><cites>FETCH-LOGICAL-c465t-3fcfd21fa8b6eb2969acce0a92b3a906acb4ae1dd5a17e1a2784471496dc9c623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.immuni.2008.08.004$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18799145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Melief, Cornelis J.M.</creatorcontrib><title>Cancer Immunotherapy by Dendritic Cells</title><title>Immunity (Cambridge, Mass.)</title><addtitle>Immunity</addtitle><description>Cancerous lesions promote tumor growth, motility, invasion, and angiogenesis via oncogene-driven immunosuppressive leukocyte infiltrates, mainly myeloid-derived suppressor cells, tumor-associated macrophages, and immature dendritic cells (DCs). In addition, many tumors express or induce immunosuppressive cytokines such as TGF-β and IL-10. As a result, tumor-antigen crosspresentation by DCs induces T cell anergy or deletion and regulatory T cells instead of antitumor immunity. Tumoricidal effector cells can be generated after vigorous DC activation by Toll-like receptor ligands or CD40 agonists. However, no single immunotherapeutic modality is effective in established cancer. Rather, chemotherapies, causing DC activation, enhanced crosspresentation, lymphodepletion, and reduction of immunosuppressive leukocytes, act synergistically with vaccines or adoptive T cell transfer. Here, I discuss the considerations for generating promising therapeutic antitumor vaccines that use DCs.</description><subject>Angiogenesis</subject><subject>Animals</subject><subject>Antigen Presentation</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapies</subject><subject>Cancer Vaccines</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD4-Positive T-Lymphocytes - metabolism</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - metabolism</subject><subject>Chemokines</subject><subject>Cross-Priming</subject><subject>Dendritic Cells - drug effects</subject><subject>Dendritic Cells - immunology</subject><subject>Dendritic Cells - metabolism</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunosuppression</subject><subject>Immunotherapy</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Ligands</subject><subject>Lymph Nodes - immunology</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Neoplasms - virology</subject><subject>Proteins</subject><subject>Tumors</subject><subject>Vaccines</subject><subject>Womens health</subject><issn>1074-7613</issn><issn>1097-4180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMorq7-A5GCoKfWTJumzUWQ-rWw4EXPIU2nmLJt16QV9t-b0gXBg8JAMvDMm8xDyAXQCCjw2yYybTt2JoopzaOpKDsgJ0BFFjLI6eF0z1iYcUgW5NS5hlJgqaDHZAF5JoRvTshNoTqNNlhNWf3wgVZtd0G5Cx6wq6wZjA4K3GzcGTmq1cbh-f5ckvenx7fiJVy_Pq-K-3WoGU-HMKl1XcVQq7zkWMaCC6U1UiXiMlGCcqVLphCqKlWQIag4yxnLgAleaaF5nCzJ9Zy7tf3niG6QrXHa_0B12I9OcpHmkOXiXxAEA8rzxINXv8CmH23nl5CQphTiGIB7is2Utr1zFmu5taZVdieBysm3bOTsW06-5VSU-bHLffhYtlj9DO0Fe-BuBtBL-zJopdMGvfLKWNSDrHrz9wvfZu6Reg</recordid><startdate>20080919</startdate><enddate>20080919</enddate><creator>Melief, Cornelis J.M.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20080919</creationdate><title>Cancer Immunotherapy by Dendritic Cells</title><author>Melief, Cornelis J.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-3fcfd21fa8b6eb2969acce0a92b3a906acb4ae1dd5a17e1a2784471496dc9c623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Angiogenesis</topic><topic>Animals</topic><topic>Antigen Presentation</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapies</topic><topic>Cancer Vaccines</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD4-Positive T-Lymphocytes - metabolism</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - metabolism</topic><topic>Chemokines</topic><topic>Cross-Priming</topic><topic>Dendritic Cells - drug effects</topic><topic>Dendritic Cells - immunology</topic><topic>Dendritic Cells - metabolism</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunosuppression</topic><topic>Immunotherapy</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Ligands</topic><topic>Lymph Nodes - immunology</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Neoplasms - virology</topic><topic>Proteins</topic><topic>Tumors</topic><topic>Vaccines</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Melief, Cornelis J.M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Immunity (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Melief, Cornelis J.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer Immunotherapy by Dendritic Cells</atitle><jtitle>Immunity (Cambridge, Mass.)</jtitle><addtitle>Immunity</addtitle><date>2008-09-19</date><risdate>2008</risdate><volume>29</volume><issue>3</issue><spage>372</spage><epage>383</epage><pages>372-383</pages><issn>1074-7613</issn><eissn>1097-4180</eissn><abstract>Cancerous lesions promote tumor growth, motility, invasion, and angiogenesis via oncogene-driven immunosuppressive leukocyte infiltrates, mainly myeloid-derived suppressor cells, tumor-associated macrophages, and immature dendritic cells (DCs). In addition, many tumors express or induce immunosuppressive cytokines such as TGF-β and IL-10. As a result, tumor-antigen crosspresentation by DCs induces T cell anergy or deletion and regulatory T cells instead of antitumor immunity. Tumoricidal effector cells can be generated after vigorous DC activation by Toll-like receptor ligands or CD40 agonists. However, no single immunotherapeutic modality is effective in established cancer. Rather, chemotherapies, causing DC activation, enhanced crosspresentation, lymphodepletion, and reduction of immunosuppressive leukocytes, act synergistically with vaccines or adoptive T cell transfer. Here, I discuss the considerations for generating promising therapeutic antitumor vaccines that use DCs.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18799145</pmid><doi>10.1016/j.immuni.2008.08.004</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1074-7613 |
| ispartof | Immunity (Cambridge, Mass.), 2008-09, Vol.29 (3), p.372-383 |
| issn | 1074-7613 1097-4180 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69581789 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Cell Press Free Archives; EZB-FREE-00999 freely available EZB journals |
| subjects | Angiogenesis Animals Antigen Presentation Antigens Antigens, Neoplasm - immunology Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cancer therapies Cancer Vaccines CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - metabolism CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Chemokines Cross-Priming Dendritic Cells - drug effects Dendritic Cells - immunology Dendritic Cells - metabolism Human papillomavirus Humans Immune system Immunosuppression Immunotherapy Inflammation - immunology Inflammation - metabolism Ligands Lymph Nodes - immunology Lymphocyte Activation - drug effects Neoplasms - immunology Neoplasms - therapy Neoplasms - virology Proteins Tumors Vaccines Womens health |
| title | Cancer Immunotherapy by Dendritic Cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A28%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20Immunotherapy%20by%20Dendritic%20Cells&rft.jtitle=Immunity%20(Cambridge,%20Mass.)&rft.au=Melief,%20Cornelis%20J.M.&rft.date=2008-09-19&rft.volume=29&rft.issue=3&rft.spage=372&rft.epage=383&rft.pages=372-383&rft.issn=1074-7613&rft.eissn=1097-4180&rft_id=info:doi/10.1016/j.immuni.2008.08.004&rft_dat=%3Cproquest_cross%3E69581789%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1550122116&rft_id=info:pmid/18799145&rft_els_id=S1074761308003750&rfr_iscdi=true |